(Q34124880)

English

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

title

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

31 July 2017

Hans R Brunner

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

publication date

1 May 2002

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

published in

Journal of Human Hypertension

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

volume

16 Suppl 2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

page(s)

S13-6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

cites work

In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001391

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.JHH.1001391

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

Dimensions Publication ID

1050674622

0 references

PubMed publication ID

11967728

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11967728

retrieved

31 July 2017

ResearchGate publication ID

11399995

0 references

(Q34124880)

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)